TY - JOUR
T1 - Basic and clinical studies of meropenem in the urological field
AU - Hata, Kazuhiro
AU - Takenaka, Tadasu
AU - Uno, Satoshi
AU - Nishitani, Yoshio
AU - Yamada, Daisuke
AU - Hayashi, Toshihide
AU - Ono, Noriaki
AU - Tugawa, Masaya
AU - Kumon, Hiromi
AU - Ohmori, Hiroyuki
AU - Kondou, Yoshikatsu
AU - Nanba, Katsuichi
AU - Akaeda, Teruaki
PY - 1992/4
Y1 - 1992/4
N2 - We studied the antibacterial activity and clinical efficacy of meropenem, a new carbapenem antibiotic, in the urological field. 1) Antibacterial activity: We measured the MICs of MEPM against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime and latamoxef. In general, the antibacterial activities of MEPM were almost equal to those of IPM but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 72.2% (13/18) for chronic complicated UTI. Bacteriologically 19 of 23 strains (82.6%) were eradicated. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, a transient elevation of GOT, GPT and LDH, and decline of Na and Cl in one case and an elevation of BUN and sCr in one case each were noted.
AB - We studied the antibacterial activity and clinical efficacy of meropenem, a new carbapenem antibiotic, in the urological field. 1) Antibacterial activity: We measured the MICs of MEPM against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime and latamoxef. In general, the antibacterial activities of MEPM were almost equal to those of IPM but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 72.2% (13/18) for chronic complicated UTI. Bacteriologically 19 of 23 strains (82.6%) were eradicated. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, a transient elevation of GOT, GPT and LDH, and decline of Na and Cl in one case and an elevation of BUN and sCr in one case each were noted.
KW - Meropenem
UR - http://www.scopus.com/inward/record.url?scp=0026780124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026780124&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.40.Supplement1_607
DO - 10.11250/chemotherapy1953.40.Supplement1_607
M3 - Article
AN - SCOPUS:0026780124
SN - 0009-3165
VL - 40
SP - 607
EP - 614
JO - Chemotherapy
JF - Chemotherapy
ER -
